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Aim  To  undertake  full  economic  evaluation  of  stapled 
hemorrhoidopexy (PPH) to establish its cost-effectiveness 
and  investigate  whether  PPH  can  become  cost-saving 
compared to conventional excisional hemorrhoidectomy 
(CH).
Methods A cost–utility analysis in hospital and health care 
system (UK) was undertaken using a probabilistic, cohort-
based decision tree to compare the use of PPH with CH. 
Sensitivity analyses allowed showing outcomes in regard 
to  the  variations  in  clinical  practice  of  PPH  procedure. 
The participants were patients undergoing initial surgical 
treatment of third and fourth degree hemorrhoids within 
a 1-year time-horizon. Data on clinical effectiveness were 
obtained from a systematic review of the literature. Main 
outcome measures were the cost per procedure at the 
hospital level, total direct costs from the health care sys-
tem perspective, quality adjusted life years (QALY) gained 
and incremental cost per QALY gained.
Results A decrease in operating theater time and hospital 
stay associated with PPH led to a cost saving compared to 
CH of GBP 27 (US $43.11, €30.50) per procedure at the hos-
pital level and to an incremental cost of GBP 33 (US $52.68, 
€37.29) after one year from the societal perspective. Cal-
culation of QALYs induced an incremental QALY of 0.0076 
and showed an incremental cost-effective ratio (ICER) of 
GBP 4316 (US $6890.47, €4878.37). Taking into consider-
ation recent literature on clinical outcomes, PPH becomes 
cost saving compared to CH for the health care system.
Conclusions PPH is a cost-effective procedure with an 
ICER of GBP 4136 and it seems that an innovative surgical 
procedure could be cost saving in routine clinical practice.
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The delivery of health care, particularly within the realms of 
new innovative surgical technologies, remains somewhat 
haphazard and subject to individual and local influences 
(1). This article looks at an innovative surgical procedure 
called stapled hemorrhoidopexy (Procedure for Prolapse 
and Hemorrhoids, PPH, Ethicon Endo-Surgery, Cincinnati, 
OH, USA) as an example of a new surgical intervention, its 
cost- effectiveness, and the potential influences that im-
pact on its availability and affordability.
As  previously  reported,  hemorrhoidal  disease  is  a  very 
common problem in most European populations, and in 
the United Kingdom (UK) has been variously estimated to 
affect between 4.4% to 36.4% of adults, accounting for 1% 
of medical consultations (2-5). Of those with symptomatic 
prolapsing hemorrhoids, some 10%-20% will undergo sur-
gical  intervention  (6,7). The  problem  that  hemorrhoidal 
disease presents to society is therefore not insignificant, 
and given that excisional hemorrhoidectomy (CH) is a rou-
tine, minor anorectal procedure that has been extensively 
studied, one might reasonably have expected a consensus 
view on the best modality of treatment.
The problem lies in the multitude of surgical treatments 
available. This includes a variety of topical agents and life-
style modifications, out-patient procedures, and excision-
al surgery. Generally, excisional surgery is reserved for the 
more severe (grades III and IV) degrees of hemorrhoidal 
prolapse (8,9). Traditionally, in European countries the pre-
ferred CH technique was the Milligan-Morgan procedure 
(10). Although effective in treating hemorrhoidal prolapse, 
Milligan-Morgan  hemorrhoidectomy  is  associated  with 
significant postoperative pain often requiring a prolonged 
hospital admission and protracted recovery (7). For this 
reason, in the last decade a novel surgical technique of sta-
pled hemorrhoidopexy has been proposed.
PPH is an innovative surgical technique that uses a spe-
cific circular stapling device (Model PPH 03 and PPH 01, 
Ethicon Endo-Surgery, Cincinnati, OH, USA) to reduce the 
hemorrhoidal  prolapse  and  excise  a  band  of  anorectal 
mucosa above the dentate line. Excessive prolapsing tis-
sue is excised and residual hemorrhoidal tissue is fixed to 
the underlying muscle. PPH as an innovation addresses the 
problem of hemorrhoidal prolapse form both an anatomi-
cal and physiological perspective, combining excision of 
the prolapse with resuspension (-pexy) and avoiding the 
painful anodermal wounds associated with other exci-
sional procedures. Since its inception, it has been the 
subject  of  intense  scientific  scrutiny.  Several  ran-
domized trials and meta-analyses have now shown it to 
be associated with significant patients benefits such as 
shorter operative times, less postoperative pain, reduced 
hospital stay, and quicker return to normal function when 
compared with standard Milligan-Morgan hemorrhoidec-
tomy (11-22). Recently, in 2007, the UK National Institute 
for Health and Clinical Excellence (NICE) issued its updated 
guidance on PPH (7) and in the appraisal process it con-
sidered two economic models of cost-effectiveness, one 
based on an independent analysis commissioned from the 
UK National Health Service (NHS) Centre for Reviews and 
Dissemination and Centre for Health Economics in York, UK 
(16) and the other submitted by the manufacturer of the 
PPH device, Ethicon Endo-Surgery (Europe) GmbH. In both 
models, the differences in cost and utilities between PPH 
and CH were small, and therefore the incremental cost-ef-
fective ratios (ICER) were sensitive to minor changes in the 
assumptions made about costs and benefits. The NICE ap-
praisal Committee noted that in both economic models 
the main influence on the ICERs was the utility estimates 
used. However, the Committee was persuaded that a clear 
utility benefit in favor of PPH was likely to exist, particularly 
in the early postoperative period.
Despite the apparent scientific support in favor of PPH, 
only 2285 (10%) of the 23 000 hemorrhoidectomy proce-
dures performed in the UK in 2008-9 were done by PPH (7). 
In other European countries, there seems to be the same 
situation. This article presents a full economic analysis of 
PPH taking into consideration recent literature on clinical 
outcomes and discusses the potential influences which 
may contribute to the disparity observed between current 
best available scientific evidence and the availability of the 
PPH procedure in clinical practice.
MethoDs
study design
A cohort-based model with a decision tree structure was de-
veloped to investigate the cost utility of PPH compared with 
CH. The model is run for two cohorts of patients with one 
group receiving a PPH on initiation and the other a CH.
The patient then goes through a recovery period during 
which a proportion of the patients may suffer a recurrent 
prolapse. The severity of the recurrent prolapse determines 
whether the patient is able to self-treat or requires further 
surgery. For this reason, the patients could follow one of 
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 1) full recovery with no recurrent prolapse;
 2) severe recurrent prolapse requiring re-operation fol-
lowed by no further prolapse;
 3) severe recurrent prolapse requiring re-operation fol-
lowed by a second recurrent prolapse;
 4) less severe recurrent prolapse which can be self treated.
The following economic parameters were included as the 
primary outcomes of the cost- effectiveness analysis: cost 
per procedure at the hospital level, total direct costs from 
the perspective of UK NHS, and Quality Adjusted Life Years 
(QALY).
The time-horizon was set at 1 year, because it has been 
suggested that there is no difference in treatment effects 
after 1 year and that any prolapse beyond that time could 
be seen as de novo hemorrhoidal prolapse, rather than dis-
ease recurrence due to treatment failure (12).
Data inputs
Effectiveness data and valuing health benefits. A system-
atic review of the current best available clinical evidence 
to evaluate the short- and long-term clinical outcomes of 
PPH compared with CH for symptomatic prolapsing hem-
orrhoids in people of any age has been recently published 
by authors of this article (17) and is used as reference for 
cost-effectiveness data in this economic evaluation. In to-
tal, 34 randomized controlled trials (RCT) and two system-
atic reviews were identified that compared PPH with CH. 
Three studies comparing other techniques than Milligan-
Morgan/Ferguson and 2 studies with poor quality or not 
available in English language were excluded. Therefore, 29 
RCTs were included in the systematic review. Data were ex-
tracted independently for each study and differences were 
analyzed with fixed and random effects models (17). The 
main clinical outcomes for the cost-effectiveness analysis 
were recurrent prolapse rate, operation time, and length 
of hospital stay.
Results from the meta-analysis of the systematic review 
(17) show that operation time for PPH was significantly 
shorter (weighted mean difference – 13.79 minutes) than 
for Milligan-Morgan hemorrhoidectomy. The percentage 
of patients who experienced a re-operation because of re-
current prolapse was 27.2% and 66.2% for CH and PPH, re-
spectively (16).
Based on the NICE, UK reference case, the relative treat-
ment effect of PPH compared to CH in terms of QALYs 
was estimated using a generic measure of health related 
quality of life (HRQoL). QALYs are calculated by multiplying 
the length of time in a particular health state by its corre-
sponding utility value. Since data were not estimated di-
rectly in any trial, they were estimated indirectly by synthe-
sizing evidence from a number of sources (7,16).
Costing
For cost calculation, the different resource use was com-
bined with the corresponding costs for the PPH or CH pro-
cedure. For the total surgery costs, time spent in operation 
theater was estimated and was combined with the cost 
per minute of surgery and the cost of the stapling device. 
The price of the hemorrhoidal circular stapler (PPH03, Ethi-
con Endo Surgery) was set at the list price of GBP 440 (US $ 
702.46, €497.02) for the year 2009. The cost of hemorrhoid-
al surgery (GBP 8.27 per minute, US $13.20, €9.34) in the 
operation theater was based on the published assessment 
report (16) for NICE appraisal TA 128. Cost of hospital stay 
amounted to be GBP 282 (US $450.21, €318.49) per day de-
termined from the NHS reference costs 2007-2008 (Excess 
Bed Day, FZ22A) (23).
In order to include the cost of recurrent hemorrhoidal pro-
lapse within a year from the NHS perspective, the probabil-
ity of re-surgery for a patient who experienced a recurrent 
prolapse was combined with the total hospital costs of the 
repeated procedure.
sensitivity analyses
One-way sensitivity analysis was performed to test the ro-
bustness of the results. The ICER is the ratio between the 
difference in costs and the difference in utility (QALYs) of 
the two interventions.
Therefore, the impact on the ICER was explored by the vari-
ation of theater and bed day costs (%).
Furthermore, it is highly likely that the hemorrhoidal re-
prolapse rate and hence the re-surgery rate for PPH may 
be lower than the 10.1% and 66% used in the base case 
model. It is very well known that these figures are influ-
enced by surgical experience and the volume of proce-
dures undertaken. For example, the long-term outcomes 
of a multicenter randomized clinical trial with 100 patients 
has demonstrated that the re-surgery rate for PPH can 
be even 50% lower than assumed in base case model 
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for CH remains roughly the same (25%) (24). Based on this 
conservative approach, a sensitivity analysis was conduct-
ed to determine how the ICER was affected when either 
or both the recurrence rate of prolapse and the re-surgery 
rate were changed.
Results
Baseline analyses
The cost calculation results of total hospital costs for each 
procedure are shown in Table 1 and amount to a total of GBP 
996 (US $1590.11, €1125.18) and GBP 1022 (US $1631.62, 
€1154.45) for PPH and CH, respectively. The decrease in time 
in the operating theater and shorter hospital stay with PPH 
led to a cost-saving of GBP 27 (US $43.11, €30.50) on the hos-
pital level compared with CH for each procedure. From the 
NHS perspective, the total treatment costs, inclusive of the 
cost of recurrent prolapse, led to an incremental cost of GBP 
33 (US $52.68, €37.29) after one year (Table 2).
QALYs were estimated as shown in Table 3 and induced an 
incremental QALY of 0.0076 (7). Improvements in HRQoL 
and decrease in post operative pain and complications 
with PPH led to greater total QALYs vs CH (16) and showed 
an ICER of GBP 4316 (US $6890.47, €4878.37), which is a 
highly cost-effective result.
sensitivity analyses
One-way sensitivity analyses for several parameters indi-
cated that the results were robust. Figure 1 shows the vari-
ation of ICER for PPH compared to CH when the operation 
theater costs and hospital stay costs are up to 30% higher 
or lower than in the base case. Even if the hospital cost 
were 30% lower, PPH would still be cost-effective with an 
ICER of GBP 21 551 (US $34 406.07, €24,354.78) from NHS 
perspective.
A sensitivity analysis was conducted to determine how the 
ICER changed with a postoperatively lower hemorrhoid-
al re-prolapse rate than calculated in the base case and 
showed that the PPH can become cost-saving compared 
taBle 1. total hospital cost of conventional excisional hemorrhoidectomy (Ch) compared to stapled hemorrhoidopexy (PPh)
Resource use Cost unit (GBP*) total costs (GBP) Difference (GBP)
Parameter Ch PPh Ch PPh
Theater (min) 31.20 17.41   8 . 2 7   258 144 -114
Hospital stay (day)   2.71   1.46 282   764 412 -353
Staple gun (unit)  0  1 440    0 440  440
Total hospital cost 1022 996   -27
*GBP 1 = us $1.60, €1.12.
taBle 2. treatment cost in one year of conventional excisional 
hemorrhoidectomy (Ch) compared to stapled hemorrhoid-
opexy (PPh) from the health care societal perspective
Probability (%)
total costs 
(GBP*)
Difference 
(GBP)
Parameter Ch PPh Ch PPh
Initial surgery 1022   996 -27
Recurrent prolapse   2.60 10.10
Resurgery for prolapse 27.20 66.20    7   6 7
Treatment cost 
(one year)
1029 1062  33
*GBP 1 = us $1.60, €1.12.
taBle 3. Incremental cost-effectiveness ratio (ICeR) of stapled 
hemorrhoidopexy (PPh) compared to conventional excisional 
hemorrhoidectomy (Ch) for the treatment of hemorrhoids
Procedure Cost (GBP*, mean) QalYs (mean)† ICeR (GBP)
PPH 1062 0.77 4316
CH 1029 0.76
Difference   3 3 0.0076
*GBP 1 = us $1.60, €1.12.
†QalY – quality adjusted life years.
Figure 1.
Incremental cost-effectiveness ratio (ICeR) sensitivity analysis for stapled 
hemorrhoidopexy  compared  to  conventional  excisional  hemorrhoid-
ectomy exploring impact of theater and bed day costs (%). GBP 1 = us 
$1.60, €1.12.501 Ribarić et al: Stapled hemorrhoidopexy, an innovative surgical procedure for hemorrhoidal prolapse
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with CH procedure also for the national health care system 
(Figure 2).
DIsCussIon
In the cost-utility analysis of PPH presented in this ar-
ticle, a decrease in operating theater time and shorter 
hospital stay associated with PPH led to a cost-saving 
compared to CH of GBP 27 per procedure at the hospi-
tal level and to an incremental cost of GBP 33 after one 
year from the societal perspective. Calculation of QALYs 
induced an incremental QALY of 0.0076 and showed an 
ICER of GBP 4316.
It should be emphasized that in the economic model base 
case presented in this article, the recurrence rate of re-pro-
lapse was set at 10.1% for PPH and it was assumed that 
2/3 or 66% of patients out of the re-prolapse group would 
require  surgical  re-intervention  (16). Taking  into  consid-
eration the published evidence (24) that suggest that re-
surgery rate for hemorrhoidal prolapse can be even 50% 
lower than assumed in conservative approach of the base 
case model (33% instead assumed 66%), the PPH proce-
dure becomes cost-saving compared to CH also for the na-
tional health care system.
Although the literature on PPH is quite extensive, only a 
few studies have included a cost-analysis (19,24-28). In one 
randomized controlled trial, the costs in one hospital were 
measured and the authors concluded that CH was more 
expensive than PPH, with the cost of the stapling device 
being more than offset by the decreased operating time 
and shorter hospital stay (19).
The previously published cost-analysis studies all have their 
limitations. Often the costs are not presented in enough 
detail and are partly taken from a single hospital. There is 
frequently not enough transparency in how the costs were 
derived and the methodology is poorly described. Further-
more, costs are often only considered at the hospital level 
and not widened to the societal level. In only one study 
were costs analyzed from the perspective of a health care 
provider, but the study used cost input from 1998 and the 
authors presented no outcomes of cost-effectiveness (27). 
The  first  full  economic  evaluation  assessing  cost-effec-
tiveness was only undertaken at the time of the NICE, UK 
health technology assessment in 2007, which concluded 
that PPH was clinically effective, offering immediate ben-
efits in terms of reduced postoperative pain and faster re-
turn to normal activities, and that consequently PPH seems 
to be a cost-effective surgical procedure (7). However, well 
known differences in surgical clinical practice where differ-
ent reccurent prolapse rates might be detected by differ-
ent surgeons were not considered.
The full economic evaluation of PPH in this article shows 
that one of the major drivers of cost-effectiveness of PPH 
may be the total hemorrhoidal re-prolapse as well as the 
total re-intervention rate following PPH and CH.
As previously published in systematic reviews of random-
ized trials, contrary to the hemorrhoidal re-prolapse rate, 
the difference between PPH and CH regarding the total 
re-intervention rates did not reach significant difference 
either for non-surgical re-interventions or surgical re-in-
terventions (7,17,22) and the rate of hospital readmissions 
after PPH compared to CH was reported to be without sig-
nificant difference.
The only significant difference between PPH and CH in 
the postoperative period was reported to be the rate of 
hemorrhoidal re-prolapse and consequently the rate of 
re-surgery regarding the re-prolapse, as a prominent sub-
group of total surgical re-intervention rates. Because of 
the conservative nature of the model, the difference in 
re-surgery rate for re-prolapse was used for calculation 
instead of the total re-intervention rate, which has been 
used by others.
This  article  expands  on  previous  cost-effectiveness 
analysis, taking into consideration the differences 
Figure 2.
sensitivity analysis for stapled hemorrhoidopexy showing incremental 
cost-effectiveness ratio (ICeR) as a function of recurrence rate of pro-
lapse and depending on a change of re-surgery rate for stapled hemor-
rhoidopexy (re-surgery rate for excisional hemorrhoidectomy remaining 
at 25%). Rhombs – re-surgery base case; squares – re-surgery -25%; tri-
angles – re-surgery -50%. GBP 1 = us $1.60, €1.12.CLINICAL SCIENCES 502 Croat Med J. 2011; 52: 497-504
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in recurrent prolapse reported between PPH and CH. In 
spite of a reported 4-fold increase in hemorrhoidal re-
prolapse  rate  following  stapled  hemorrhoidopexy,  the 
PPH  procedure  remains  highly  cost-effective  and  can 
even lead to cost savings. The explanation is likely based 
on  the  evidence  that  about  50%  of  patients  with  the 
hemorrhoidal  re-prolapse  postoperatively  do  not  seek 
further surgical intervention and are quite satisfied with 
the surgical results (17). Also, it appears to be particularly 
true if surgeon experience and surgical volume increase 
with a concomitant decrease in the re-prolapse and re-
intervention rates.
A limitation of the presented cost utility analysis is that the 
economic model is confined to a one year time horizon. 
This however is not considered a significant limitation as 
there appears to be convergence in utilities by one year. 
Clinical opinion also considers that prolapse beyond this 
point is a new prolapse, not necessarily a recurrence of pre-
viously prolapsing hemorrhoids. Furthermore, the model 
did not consider complications and symptoms, other than 
prolapse. However, the difference between PPH and CH re-
garding the total re-intervention rates did not reach signifi-
cant difference either for non-surgical re-interventions or 
surgical re-interventions (7,17,22).
If seen in a broader health care context, given the positive 
recommendations of the 2007 NICE, UK guidance and its 
obvious international impact on the European network for 
Health Technology Assessment (EUnetHTA), it is therefore 
somewhat surprising that disparities still exist within the 
European health care systems between the availability of 
an innovative surgical procedure such as PPH and current 
best available scientific evidence.
In terms of local health care policy and delivery, manag-
ers are frequently dissuaded by the cost of new surgical 
technologies in comparison to traditional techniques. The 
manager with targets and financial budgets to meet is like-
ly to be less concerned by any societal benefits that a new 
procedure may offer than the immediate costs to his insti-
tution. Unless managers are unaware or choose to ignore 
international NICE guidance, this should not influence the 
provision of stapled hemorrhoidopexy.
From a clinical perspective, of the three possible process-
es which might underlie the variation in surgical prac-
tice (patient referral patterns, choice of surgical inter-
vention, and health care delivery), it therefore appears 
that it is the clinician’s preference that remains the 
predominant factor. It is hoped that the economic evalu-
ation presented in this study, in line with previous NICE 
guidance,  will  reassure  clinicians  that  stapled  hamor-
rhoidopexy performed with PPH device is a cost-effective 
treatment, and even when recurrent prolapse is taken 
into consideration, it has the potential to be a cost-saving 
surgical procedure. Further education and training in the 
proper technique of PPH should eliminate any remaining 
unfamiliarity and help to eliminate the current disparity 
between health care provision and current best available 
evidence.
PPH seems to be an attractive alternative to CH in patients 
with symptomatic, prolapsing hemorrhoids. Offering obvi-
ous clinical advantages, including less postoperative pain, 
reduced hospital stay, and quicker return to normal func-
tion, PPH presents a cost-effective procedure from the so-
cietal perspective with an ICER of GBP 4316. It seems that 
an innovative surgical procedure such as PPH could be 
even cost-saving in routine clinical practice.
To ensure uniformity in health care provision, the variation 
in individual surgical practice needs to be addressed, and 
clinicians and managers made aware of the economic ar-
guments in favor of stapled hemorrhoidopexy.
In the authors’ opinion, any residual doubts relating to 
potential cost-savings and unfamiliarity with an innova-
tive surgical procedure such as stapled hemorrhoidopexy 
can be overcome with appropriate and continuous sur-
gical training combined with the rigorous implementa-
tion of evidence-based medicine in health care decision 
making.
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